3-(oxiranylmethoxy)-2-(phenylmethoxy)benzaldehyde | 137578-44-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(oxiranylmethoxy)-2-(phenylmethoxy)benzaldehyde
• 英文别名: (R)-2-benzyloxy-3-(2,3-epoxypropoxy)benzaldehyde；3-(Oxiran-2-ylmethoxy)-2-phenylmethoxybenzaldehyde
• CAS: 137578-44-0
• 化学式: C₁₇H₁₆O₄
• 分子量: 284.312
• InChiKey: WTDRABIAAOFDAS-UHFFFAOYSA-N

物化性质

• 沸点：
  453.5±30.0 °C(Predicted)
• 密度：
  1.235±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  48.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(oxiranylmethoxy)-2-(phenylmethoxy)benzaldehyde 在 palladium on activated charcoal 4-二甲氨基吡啶 、 四丁基氟化铵 、 sodium methylate 、 potassium carbonate 、 三乙胺 、 环己烯 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 二氯甲烷 、 xylene 为溶剂， 反应 48.5h， 生成 8-(4-Oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-8-ylmethyl)-7,8-dihydro-3H-6,9-dioxa-3-aza-cyclopenta[a]naphthalene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Novel indolodioxanes with antihypertensive effects: potent ligands for the 5-HT1A receptor

  摘要：

  The synthesis and biological evaluation of a new family of tricyclic indolodioxanes is described. These compounds all contain the 2,3-dihydro-7H-1,4-dioxino[2,3-e]indole nucleus and bear substituents at the 2 and/or 8 positions. Thirteen members of this class were prepared and shown to be potent ligands for the 5-HTA receptor, with several compounds displaying subnanomolar inhibition constants. These compounds also bind to the dopamine D-2 receptor, but generally with higher inhibition constants than those for 5-HT1A. Certain members of this novel structural class show in vivo activity in the mouse hypothermia assay. One of these compounds, U-86192A, has been shown to have antihypertensive effects in the cat, completely eliminating sympathetic nerve discharge at 1 mg/kg iv and lowering mean arterial pressure to 50% pretreatment levels. These effects can be reversed by the administration of spiperone, indicating that U-86192A is acting via a central serotonergic mechanism.

  DOI：

  10.1021/jm00094a021
• 作为产物：
  描述：

  2-(benzyloxy)-3-hydroxybenzaldehyde 、 环氧氯丙烷 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以96%的产率得到3-(oxiranylmethoxy)-2-(phenylmethoxy)benzaldehyde
  参考文献：
  名称：

  Novel indolodioxanes with antihypertensive effects: potent ligands for the 5-HT1A receptor

  摘要：

  The synthesis and biological evaluation of a new family of tricyclic indolodioxanes is described. These compounds all contain the 2,3-dihydro-7H-1,4-dioxino[2,3-e]indole nucleus and bear substituents at the 2 and/or 8 positions. Thirteen members of this class were prepared and shown to be potent ligands for the 5-HTA receptor, with several compounds displaying subnanomolar inhibition constants. These compounds also bind to the dopamine D-2 receptor, but generally with higher inhibition constants than those for 5-HT1A. Certain members of this novel structural class show in vivo activity in the mouse hypothermia assay. One of these compounds, U-86192A, has been shown to have antihypertensive effects in the cat, completely eliminating sympathetic nerve discharge at 1 mg/kg iv and lowering mean arterial pressure to 50% pretreatment levels. These effects can be reversed by the administration of spiperone, indicating that U-86192A is acting via a central serotonergic mechanism.

  DOI：

  10.1021/jm00094a021

文献信息

• Heterocyclcarboxamide derivatives and their use as therapeutic agents
  申请人：Knoll Aktiengesellschaft

  公开号：US05935973A1

  公开（公告）日：1999-08-10

  Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which A is methylene or O; B is methylene or O; g is 0,1,2,3 or 4; R.sub.1 is an optional substituent; U is an alkylene chain optionally substituted by one or more alkyl; Q represents a divalent group containing nitrogen atoms; and T represents CO.HET, have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behavior, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.

  化合物的化学式I ##STR1## 及其药用盐，在其中A为亚甲基或氧；B为亚甲基或氧；g为0,1,2,3或4；R.sub.1为可选取代基；U为一种烷基链，可选择地被一个或多个烷基取代；Q代表含氮原子的二价基团；T代表CO.HET，在治疗中枢神经系统疾病方面具有用途，例如抑郁症、焦虑、精神病（例如精神分裂症）、迟发性运动障碍、帕金森病、肥胖症、高血压、托瑞特综合症、性功能障碍、药物成瘾、药物滥用、认知障碍、阿尔茨海默病、老年性痴呆、强迫行为、恐慌发作、社交恐惧症、进食障碍和厌食症、心血管和脑血管疾病、非胰岛素依赖型糖尿病、高血糖、便秘、心律失常、神经内分泌系统疾病、应激、前列腺肥大和痉挛性疾病。
• [EN] HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] DERIVES HETEROCYCLYLCARBOXAMIDES ET LEUR UTILISATION EN TANT QU'AGENTS THERAPEUTIQUES
  申请人：KNOLL AKTIENGESELLSCHAFT

  公开号：WO1997003071A1

  公开（公告）日：1997-01-30

  (EN) Compounds of formula (I), and pharmaceutically acceptable salts thereof in which A is methylene or O; B is methylene or O; g is 0, 1, 2, 3 or 4; R1 is an optional substituent; U is an alkylene chain optionally substituted by one or more alkyl; Q represents a divalent group containing nitrogen atoms; and T represents CO.HET, have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.(FR) L'invention concerne des composés représentés par la formule (I) ainsi que des sels pharmaceutiquement acceptables de ces composés. Dans la formule (I), A est méthylène ou oxygène, B est méthylène ou oxygène, g vaut 1, 2, 3 ou 4, R1 est un substituant facultatif, U est une chaîne alkylène facultativement substituée par un ou plusieurs alkyles, Q représente un groupe divalent contenant des atomes d'azote et T représente le groupe CO.HET. Lesdits composés s'avèrent utiles dans le traitement des troubles du système nerveux central, tels que la dépression, l'anxiété, les psychoses (schizophrénie, par exemple), les dyskinésies tardives, la maladie de Parkinson, l'obésité, l'hypertension, la maladie de Gilles de la Tourette, les troubles de la sexualité, la toxicomanie, la pharmacodépendance, les troubles cognitifs, la maladie d'Alzheimer, la démence sénile, la psychonévrose obsessionnelle, les crises de panique, les névroses phobiques, les troubles de l'alimentation et l'anorexie, les troubles cardio-vasculaires et cérébro-vasculaires, le diabète sucré non-insulino-dépendant, l'hyperglycémie, la constipation, l'arythmie, les troubles du système neuro-endocrinien, le stress, l'hypertrophie prostatique et la spasticité.

  化合物的公式(I)，以及其中的药学上可接受的盐，其中A是亚甲基或氧原子；B是亚甲基或氧原子；g为0、1、2、3或4；R1是可选的取代基；U是一种可以被一个或多个烷基取代的烷基链；Q代表含有氮原子的二价基团；T代表CO.HET，可用于治疗中枢神经系统疾病，例如抑郁症、焦虑症、精神病（例如精神分裂症）、迟发性运动障碍、帕金森病、肥胖症、高血压、杜雷特综合症、性功能障碍、药物成瘾、药物滥用、认知障碍、阿尔茨海默病、老年性痴呆、强迫症行为、惊恐发作、社交恐惧症、进食障碍和厌食症、心血管和脑血管疾病、非胰岛素依赖性糖尿病、高血糖、便秘、心律失常、神经内分泌系统疾病、压力、前列腺肥大和痉挛症。
• HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：ABBOTT GmbH & Co. KG

  公开号：EP0839145B1

  公开（公告）日：2003-11-05
• US5935973A
  申请人：——

  公开号：US5935973A

  公开（公告）日：1999-08-10
• Novel indolodioxanes with antihypertensive effects: potent ligands for the 5-HT1A receptor
  作者：Michael D. Ennis、Mark E. Baze、Martin W. Smith、Charles F. Lawson、Robert B. McCall、Robert A. Lahti、Montford F. Piercey

  DOI：10.1021/jm00094a021

  日期：1992.8

  The synthesis and biological evaluation of a new family of tricyclic indolodioxanes is described. These compounds all contain the 2,3-dihydro-7H-1,4-dioxino[2,3-e]indole nucleus and bear substituents at the 2 and/or 8 positions. Thirteen members of this class were prepared and shown to be potent ligands for the 5-HTA receptor, with several compounds displaying subnanomolar inhibition constants. These compounds also bind to the dopamine D-2 receptor, but generally with higher inhibition constants than those for 5-HT1A. Certain members of this novel structural class show in vivo activity in the mouse hypothermia assay. One of these compounds, U-86192A, has been shown to have antihypertensive effects in the cat, completely eliminating sympathetic nerve discharge at 1 mg/kg iv and lowering mean arterial pressure to 50% pretreatment levels. These effects can be reversed by the administration of spiperone, indicating that U-86192A is acting via a central serotonergic mechanism.